Nausea for 12 Hours vs. Sexual Dysfunction for Years: The Side-Effect Math Nobody's Doing on Mental Health Drugs

A single dose of a psychedelic causes nausea and headache that resolve within a day. A daily SSRI or Wellbutrin can cause sexual dysfunction in up to half of patients for as long as they're on it — and one of the biggest names in the daily-pill business has a $757 million fraud settlement to show for how it got there.

Two kinds of mental-health drugs are on the market right now, and the side-effect conversation around them almost never gets put side by side. One kind gets administered once, in a clinic, under supervision — the side effects show up that day and are gone within 24 to 48 hours. The other kind gets swallowed every morning, often for years, and the side effects don't resolve until you stop taking it — if they resolve at all. We ran the actual numbers on both, and added in something usually left out of the comparison entirely: the legal record of what one of the biggest names in the daily-pill business did to get its drug approved and prescribed at scale.

The One-Time Reckoning

Definium's DT120 — the LSD candidate we've been tracking through two positive Phase 3 trials — has real, disclosed adverse-event data from Voyage and Panorama. On dosing day, at the 100 μg dose: illusion in 68% of patients, nausea in 37%, headache in 24%. The overall treatment-emergent adverse event rate was 94.8%, against 62.9% for placebo — a real gap, not nothing. But discontinuation because of it was 10.4%, statistically indistinguishable from the 10.3% who quit the placebo arm. People don't leave the trial over it. A separate meta-analysis of therapeutic psilocybin found a similar shape: headache in 55% of participants at 12 hours, nausea in 39%, resolved within 24 to 48 hours, no severe anxiety, no panic attacks, no acute suicidality recorded. Modern LSD trials report the same pattern — mild, transient, gone by the next day.

The Daily Reckoning

Now the drugs already in 53.5 million American medicine cabinets. SSRI-associated sexual dysfunction is one of the most under-discussed numbers in psychiatry — estimates range from 30% to over 80% depending on methodology, with a realistic midpoint around 40-50%, and it lasts exactly as long as the prescription does. Antidepressant discontinuation syndrome00133-0/fulltext) hits roughly 15-20% of patients who stop, and the variance by drug is brutal: 14% for fluoxetine, but 60% for sertraline and 66% for paroxetine — Paxil. About 3% get symptoms severe enough to send them back to the pharmacy. None of this is one bad afternoon. This is the ongoing cost of staying on the drug, and it doesn't show up in a 24-hour resolution window because there isn't one.

	Single-dose psychedelic (clinical trial)	Daily SSRI / Wellbutrin
Most common side effects	Nausea, headache, transient illusion	Sexual dysfunction, discontinuation symptoms
Typical incidence	24-68%, dose-dependent	30-80% (sexual), 15-66% (discontinuation, drug-dependent)
Duration	Hours to 48 hours, one time	As long as you're on the drug — sometimes longer
Trial discontinuation because of it	~10%, same as placebo	N/A — most patients stay on despite it

The Disguised Drug

Wellbutrin deserves its own line item, because it isn't just another SSRI-adjacent pill — it's chemically a cathinone, the same drug family as the khat-derived stimulants sold illegally as "bath salts." Bupropion is, per the pharmacology literature, the only cathinone in legitimate pharmaceutical use — every other one is a street drug. Psychiatrist Dr. Thomas Cook, writing on Substack, argues the drug was deliberately rebranded away from its stimulant identity in 1990 — its international generic name was literally amfebutamone until 2000 — to distance it from a federal crackdown on stimulants and diet pills; that's his reading of the motive, not an established fact, but the underlying chemistry and timeline check out. What isn't in dispute: bupropion shows up often enough in poison-control data to have earned a nickname in the case-report literature — "the poor man's cocaine." Insufflation abuse — crushing and snorting it — produces seizures in roughly a third of reported cases, alongside tachycardia in more than half.

The Company That Got Caught

Here's the part that belongs in any honest side-effect comparison and almost never makes it in: GlaxoSmithKline, Wellbutrin's manufacturer, pled guilty in 2012 to the largest healthcare fraud settlement in US history — $3 billion total, with $757,387,200 specifically attributed to the criminal misbranding of Paxil and Wellbutrin. From 1999 to 2003, GSK sales reps promoted Wellbutrin for weight loss, sexual dysfunction, and ADHD — none of them approved uses at the time — paying doctors to tout it at resort meetings and running sham "independent" education programs. The same settlement covered Paxil's Study 329: an internal 1998 memo acknowledged the trial had failed to beat placebo in depressed teenagers, and the published paper said the opposite, while downplaying a signal for suicidal thinking that a 2015 BMJ reanalysis later confirmed was real. This isn't ancient history dredged up to score a point — it's the same manufacturer, the same era, the same settlement, and it's why Wellbutrin isn't in our anxiolytic tables at all: it was never approved for anxiety, and its own case-report literature suggests it can make anxious and OCD-adjacent presentations worse, not better.

Merck's Vioxx is the other name that belongs in this company. Pulled from the market in 2004 after being shown to double the risk of heart attack and stroke, it cost Merck $4.85 billion in settlements — a reminder that concealed risk in this industry isn't a one-company problem, and that "on the market" has never meant "fully understood."

The Uncomfortable Symmetry

Here's where it gets complicated for anyone hoping for a clean villain. Wellbutrin and every SSRI carry the exact same FDA black-box warning — increased suicidal thinking and behavior in patients under 25, added in 2004 after a Columbia University review of 23 trials found the risk was real (odds ratio 1.71). That warning doesn't exist for DT120 or psilocybin, in part because neither has enough years of real-world use to have generated one — the honest caveat, not a small one. A supervised, single 100 μg dose in a clinical trial with a therapist in the room is not the same risk profile as taking a compound recreationally, unsupervised, with no screening for cardiac or psychiatric vulnerability. The psychedelic side of this comparison looks better specifically because it's still operating inside tightly controlled trial conditions that the daily-pill side left behind decades ago.

That's the actual honest version of this story: not that one class of drugs is safe and the other isn't, but that the industry has a documented pattern — Paxil's hidden data, Wellbutrin's disguised chemistry, Vioxx's concealed cardiac risk — of the real cost only becoming visible after the drug had years, sometimes decades, of unsupervised daily use behind it. The psychedelic trials publishing 37% nausea rates in a press release, on day one, are operating under a level of disclosure the legacy drugs never had to meet when they launched.

This is analysis and historical reporting, not medical advice. Do not stop or change any prescribed medication without talking to your prescriber — abrupt discontinuation of SSRIs and other antidepressants carries its own real withdrawal risk, described above. No compound discussed here is being presented as safer in all respects than another; the comparison is about disclosure and duration, not a blanket safety ranking.